Further clinical data are needed to assess whether dual EP2/EP4 antagonists can tackle the extensive immune suppressive effects mediated by PGE2 within the TME, thereby restoring the anti-tumor immunity of the host and opening the possibility to overcome resistance to CPIs due to a non-inflamed tumor environment. Here, PTGER4 is linked to neoplasm.